AUSTIN, Texas, Jan. 2, 2019 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has completed its previously announced acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million in combined stock, asset and inventory purchases. The acquisition is expected to contribute $40 million to $50 million in revenue to Luminex in 2019. “We are pleased... Read more
AUSTIN, Texas, Oct. 18, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has signed a definitive agreement to acquire MilliporeSigma’s flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a Stock and Asset Purchase Agreement and approximately $5.1 million in committed inventory purchases. The deal... Read more
AUSTIN, Texas, Oct. 18, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has signed a definitive agreement to acquire MilliporeSigma’s flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a Stock and Asset Purchase Agreement and approximately $5.1 million in committed inventory purchases. The deal... Read more
AUSTIN, Texas, June 13, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced the company recently began clinical studies for the Gastrointestinal (GI) Assay on the VERIGENE® II System, its new sample to answer benchtop molecular diagnostic system in development. The VERIGENE System enables clinicians to rapidly identify the pathogens responsible for some of the... Read more
AUSTIN, Texas, Feb. 6, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7th Annual Global Healthcare Conference to be held February 14-15, 2018, in New York, NY. The investor presentation will begin at 10:30 a.m. Eastern time on Thursday, February 15, 2018. The presentation will be webcast live... Read more
AUSTIN, Texas, Nov. 14, 2017 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference to be held November 28 -29, 2017, in New York. The investor presentation will begin at 8:00 a.m. Eastern time on Wednesday, November 29, 2017. The presentation will be webcast live... Read more
AUSTIN, Texas, Nov. 14, 2017 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference to be held November 28 -29, 2017, in New York. The investor presentation will begin at 8:00 a.m. Eastern time on Wednesday, November 29, 2017. The presentation will be webcast live... Read more
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has... Read more
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has... Read more
AUSTIN, Texas, Sept. 19, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald’s Global Healthcare Conference to be held September 25 -27, 2017, in New York, NY. The investor presentation will begin at 10:20 a.m. Eastern time on Tuesday, September 26, 2017. The presentation will be webcast live and may... Read more